Improvement of peripheral neuropathy in a patient with antineutrophil cytoplasmic antibody-negative eosinophilic granulomatosis with polyangiitis by additional mepolizumab

Improvement of peripheral neuropathy in a patient with antineutrophil cytoplasmic antibody-negative eosinophilic granulomatosis with polyangiitis by additional mepolizumab

Abstract Background Eosinophilic granulomatosis with polyangiitis (EGPA) is a vasculitis characterized by abnormally high eosinophils and frequent peripheral neuropathy. Mepolizumab is an approved therapy for EGPA, but its efficacy against peripheral neuropathy remains unknown. Case presentation A 4...

Full description

Bibliographic Details
Main Authors: Yoshiro Kai, Masanori Yoshikawa, Masayuki Matsuda, Kentaro Suzuki, Hiroya Ohara, Naohiko Iguchi, Takehito Kasamatsu, Kenji Uno, Nobuhiro Fujioka, Yukio Fujita, Shigeo Muro
Format: Article
Language:English
Published: BMC 2022-02-01
Series:Allergy, Asthma & Clinical Immunology
Subjects:
Asthma
Eosinophilic granulomatosis with polyangiitis
IL-5
Mepolizumab
Peripheral neuropathy
Online Access:https://doi.org/10.1186/s13223-022-00653-7

Internet

https://doi.org/10.1186/s13223-022-00653-7

Similar Items